Umeclidinium bromide and vilanterol trifenatate inhalation powder

Hospital Pharmacy

Volumn 49, Issue 6, 2014, Pages 554-562

  Cada, Dennis ^b   Ingram, Kyle ^a   Leonard, James ^a   Baker, Danial ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Drug Information Center College of Pharmacy Washington State University Spokane ^*

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; UMECLIDINIUM; VILANTEROL; VILANTEROL TRIFENATATE;

ABDOMINAL PAIN; ASTHENIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACOLOGY; CONJUNCTIVITIS; COUGHING; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG UTILIZATION; DYSPEPSIA; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MUSCULOSKELETAL CHEST PAIN; POWDER; PRACTICE GUIDELINE; PRURITUS; REVIEW; SUPRAVENTRICULAR PREMATURE BEAT; THORAX PAIN; VOMITING; XEROSTOMIA;

EID: 84902463753     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4906-554     Document Type: Review

References (20)

1. Anoro Ellipta [package insert]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.
2. Combivent [package insert]. Ridgefi eld, CT: Boehringer Ingelheim Pharmaceuticals Inc; August 2012.
3. DuoNeb [package insert]. Napa, CA: Dey Pharma LP; May 2012.
4. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970-979.
5. Salmon M, Luttman MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): A novel, long-Acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260-270.
6. Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-Acting beta2-Adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218-230.
7. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-Acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256-264.
8. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-Acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393-399.
9. Lvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012;40(3):570-579.
10. Cahn A, Tal-Singer R, Pouliquen IJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: Two randomized studies. Clin Drug Investig. 2013;33(7):477-488.
11. Cahn A, Mehta R, Preece A, Blowers J, Donald A. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults defi cient in CYP2D6 activity: A double-blind, randomized clinical trial. Clin Drug Investig. 2013;33(9):653-664.
12. Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: A randomized crossover trial [published online ahead of print December 17, 2012]. PLoS One. 2012;7(12):e50716.
13. Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-Acting beta(2)-Adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013;41(1):89-100.
14. Feldman G, Walker RR, Brooks J, Mehta R, Crater G.-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465-471.
15. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www. goldcopd.org. Published February 2013. Accessed December 17, 2013.
16. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Effi cacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538-1546.
17. Celli BR, Crater G, Kilbride S, et al. A 24-week randomized, double-blind, placebo-controlled study of the effi cacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD [abstract]. Am J Respir Crit Care Med. 2013;187:A2435.
18. Celli BR, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: A randomized, controlled study [published online ahead of print January 2, 2014]. Chest.
19. Anzueto A, Decramer M, Kaelin T, et al. The effi cacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD [abstract]. Am J Respir Crit Care Med. 2013;187:A4268.
20. Rosebraugh CJ. NDA approval letter: Anoro Ellipta (umeclidinium/ vilanterol powder for inhalation; NDA 203975). US Food and Drug Administration Web site. http://www.accessdata. fda.gov/drugsatfda-docs/appletter/2013/ 203975Orig1s 000ltr.pdf. Published December 18, 2013. Accessed January 2, 2014.